Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OCTOVA: Paclitaxel, olaparib and cediranib in platinum-resistant ovarian cancer.

OCTOVA trial logo

PRIMARY PUBLICATION

British Journal of Cancer 20th January 2023

Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer

Lay Summary

A lay summary of the OCTOVA trial can be found on the CRUK website at this link:

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-different-treatments-for-women-who-have-ovarian-cancer-octova

Cookies on this website

OCTOVA: Paclitaxel, olaparib and cediranib in platinum-resistant ovarian cancer.

PRIMARY PUBLICATION

Lay Summary

On this page